Abstract

3K3A-APC is a recombinant variant of activated protein C (APC) with > 90% reduced anticoagulant activity but preserved cell signaling activity. Benefical effects are mediated by its antiapoptotic direct neuronal protective and vasculoprotective effects including protection of blood-brain barrier (BBB) integrity as well as anti-inflammatiory activity as shown in multiple animal models of large ischemic stroke (middle cerebral artery occlusion) and neurodegeneration. These preclinical studies led to a successfully completed phase II clinical trial of 3K3A-APC for ischemic stroke (RHAPSODY). RHAPSODY trial showed that 3K3A-APC is safe and may reduce hemorrhage in patients that were treated with tPA and/or thrombectomy standard of care therapy for stroke. Even though the protective effects of 3K3A-APC are well known to be mediated by biased signaling via protease activated receptor 1 (PAR1) activation, the role of PAR1 has not been studied in ischemic white matter stroke. In the present study, we used a mouse model of white matter stroke induced by injecting a vasoconstrictor N 5 -(1-Iminoethyl)-L-ornithine (L-NIO) into the corpus callosum. Our results suggest that 4 hrs post-treatment with 3K3A-APC (0.2 mg/kg) reduced lesion volumes by about ~67% (cresyl violet staining and T2w MRI), which was associated with reduced BBB leakage (fibrinogen staining and DCE-MRI), and improved function of oligodendrocytes (OLS, Olig2+CNPase+) and oligodendrocyte precursor cell (OPCs, Olig2+PDGFRα+) at 1 and 7 days after stroke. Beneficial effects of 3K3A-APC were associated with reduced axonal damage on diffusion tensor MRI, and improved behavioral performance on adhesive removal and grid walking tests. We next showed that PAR1 is expressed in all major cell types in the white matter (e.g., OLS, OPCs, microglia and astrocytes) and that silencing PAR1 with small interfering RNA (siRNA) abolishes the protective effect of 3K3A-APC in this model. Taken together, our data suggest that 3K3A-APC is protective in ischemic white matter disease via PAR1 mediated signaling, which improves oligovascular integrity and neuronal survival.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call